AUTHORS
Junlei Jia, Zheng Song2, Yidan Zhang3, Zechao Hu4, Xianhuo Wang, PhD5, Huilai Zhang, PhD6
AFFILIATIONS
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
4 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
5 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
6 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
ABSTRACT
Introduction:
Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a distinct extranodal malignancy with an increased risk of central nervous system recurrence. However, systematic studies are currently lacking due to its rarity. This study conducted an integrated clinical and molecular analysis to elucidate its unique biology compared to nodal and IP-DLBCL.
Methods:
This single-center study enrolled 705 DLBCL patients (136 PB, 363 nodal, and 206 IP), excluding those with secondary extranodal involvement. Baseline clinical characteristics and survival data were retrospectively collected. Inverse probability of treatment weighting (IPTW) was applied to mitigate potential confounders. We performed DNA (n=223; 63 PB, 127 nodal, 33 IP) and RNA sequencing (n=121; 58 PB, 48 nodal, 15 IP) on the DLBCL cohort. The LymphGen algorithm was applied to subcategorize patients based on their genetic alteration profiles. Immune cell fractions and immune signatures were evaluated using xCell and ssGSEA, respectively. We performed single-cell RNA sequencing from one PB-DLBCL patient to characterize tumor B-cell heterogeneity and the tumor microenvironment.
Results:
Among all 136 patients with PB-DLBCL, the median age at diagnosis was 57 years (range, 21-89 years). seventy-two cases (52.9%) were considered non-GCB phenotype and 35 cases (25.7%) GCB. The bilateral breast involvement occurred in 8 patients (5.9%), and ki-67 >80% was observed in 87 (64.0%) patients. Survival analysis showed that the 5-year PFS and OS rates of PB-DLBCL were 74% and 85%, respectively. Following IPTW adjustment, IP-DLBCL exhibited the poorest survival outcomes. Notably, PB-DLBCL showed superior weighted PFS initially but worse late-phase outcomes compared to nodal DLBCL. We next examined disease-specific death patterns across the three groups and found IP-DLBCL showed a pronounced peak of deaths within the first year, indicating a high risk of early mortality. In contrast, PB-DLBCL displayed a much more prolonged distribution of death events over time, whereas nodal DLBCL exhibited an intermediate pattern.
In terms of the mutational landscape, the most prevalent mutations in PB-DLBCL were PIM1 (59%), followed by KMT2D (41%), KMT2C (35%), CD79B (33%), IGLL5 (25%), SPEN (25%), and MYD88 (22%). Compared to nodal DLBCL, PB and IP-DLBCL showed enriched BCR/NF-κB pathway mutations. Mutations in epigenetic regulators and NOTCH2 pathway were more frequent in PB-DLBCL, while alterations in immune evasion genes, such as CIITA and CD58, were relatively enriched in IP-DLBCL. The mutation rates of TP53 in nodal, PB, and IP-DLBCL were 29%, 14% and 9%, and PIM1 mutation were 34%, 59% and 73%, respectively. Among LymphGen-classifiable patients, PB-DLBCL was mainly MCD and EZB, IP-DLBCL mostly MCD, and nodal DLBCL showed a balanced distribution. MCD and EZB remained the predominant subtypes among patients with disease progression within 5 years.
Compared with normal breast tissue, PB-DLBCL showed a marked enrichment of B-cell signatures and a reduction in stromal cell signatures. Both PB and IP-DLBCL, as extranodal lymphoma, exhibited lower T cells and macrophages infiltration than nodal DLBCL. PB-DLBCL showed enrichment of NOTCH and TGF-β signaling, accompanied by weaker IFN-related immune activation signatures compared with nodal DLBCL. Single-cell RNA sequencing further revealed a B-cell-dominant, immune-poor microenvironment. InferCNV analysis demonstrated widespread copy number alterations across tumor B-cell populations and distinct CNV patterns among clusters, highlighting marked intratumoral heterogeneity. Integrative analyses of transcription factor activity, differentiation potential, and gene signatures identified functionally diverse malignant B-cell states. BC1 cluster exhibited NF-κB and antigen-presenting cell programs; BC2/3 showed enhanced activated B-cell like, BCR signaling, migration and immune checkpoint signatures; whereas BC4 through BC7 displayed highly proliferative and cell-cycle-associated programs.
Conclusions:
PB-DLBCL exhibits persistent long-term mortality, underscoring the importance of sustained follow-up and long-term disease management. Our comprehensive analysis defines PB-DLBCL as a distinct biological entity characterized by unique molecular features, recurrent epigenetic alterations, and a B-cell-dominant, immune-poor microenvironment, providing insights into potential precision therapeutic strategies.
DISCLOSURES
Junlei Jia: No relevant conflicts of interest to declare.